A pleasure catching up with our European Editorial Board member Stefan Evers (University of Münster, Germany). He spoke to us about miscellaneous idiopathic headache disorders, the topic of his presentation in the ‘Integrative Treatment of Idiopathic Headache Disorders’ session.
1. What is covered by the term ‘miscellaneous idiopathic headache disorders’? (0:05)
2. What are the guideline recommended treatments for these disorders? (0:40)
3. What are the major unmet needs in the treatment of miscellaneous idiopathic headache disorders? (1:23)
4. How can drug treatment and interventional treatment be integrated for patients with these disorders? (2:08)
5. Are there any emerging treatments for these disorders? (2:55)
Speaker disclosure: Stefan Evers reports having received honoraria for consultation and lectures over the last 3 years from Allergan, Eli Lilly, Novartis and Teva.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Headache Disorders
Robert Music, The Migraine Trust: Improving migraine care – ensuring patient-focussed diagnosis and treatment in the UK
“Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges around diagnosis, care and access to the right treatment. ” – Rob Music, CEO, The […]
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!